Patient Participation Groups: A voice for patients for 50 years

Jun 8, 2022

Written by Dom Partridge, Medical Writer

6th to 13th June 2022 is Patient Participation Group (PPG) Awareness Week; aiming to raise the profile of PPGs within primary healthcare.

The first Patient Participation Group

The first PPG was set up in 1972 by Dr Peter Pritchard at his practice in Berinsfield, near Oxford, and in 1975 he published a paper in the British Medical Journal detailing his observations. Although this paper was published nearly 50 years ago, the issues that members raised still resonate today. For example, it’s interesting to read that receptionists struggled to fit everyone in, while staffing difficulties at weekends and evenings, and the need for limited non-urgent consulting time in “unsocial hours”, were discussed. Dr Pritchard goes on to note that after listening to patients’ concerns and thoughts, a booklet on “hints on keeping well” was written and distributed, and a chiropody service with transport for older people was organised.

Current Patient Participation Groups

In the 50 years since Dr Pritchard’s innovation, PPGs have become commonplace throughout the country. Their role however has remained similar, they now:

  • Advise the practice on the patient perspective
  • Organise health promotion events
  • Communicate with the wider patient body
  • Run volunteer services and support groups to meet local needs
  • Carry out research into the views of those who use the practice (and their carers)
  • Influence the practice or the wider NHS to improve commissioning
  • Fundraise to improve the services provided by the practice.

You may have noticed that one aspect of PPGs in particular has remained consistent; communication.

Communication is at the heart of what we do at Source Health Economics.

Our team of medical writers are experienced in developing clear and concise written materials, which effectively communicate evidence-based messages. Our writing is tailored to the audience, whether that is colleagues in the pharmaceutical/medical device industry, health technology assessment body assessors, clinicians, payers, or patient groups. If you are interested in finding out more about our value communication services, please contact us at Source Health Economics, an independent consultancy specialising in evidence generation, health economics, and communication.


More Insights

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Written by Jo Wallis, Head of Commercialisation and Pricing Strategy   The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the ... Read more

The role of orphan drug designations in driving research and innovation for rare diseases

The role of orphan drug designations in driving research and innovation for rare diseases

Written by Emma Bartram, Associate Systematic Review Analyst   A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). ... Read more

HTA monthly update

HTA monthly update

By Toby Hobbs   Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment ... Read more

Evaluating Health Inequalities: NICE’s Modular Update

Evaluating Health Inequalities: NICE’s Modular Update

Written by Paloma Charlesworth (Assistant Project Manager)   Background  Health inequalities are systematic, avoidable, and unjust differences in health outcomes between patient groups. Despite decades of policy and research, they not ... Read more